Effect of Captopril on GLS in Duchenne Myodystrophy
ConditionEffect of Drug
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexMale
Age6+
SponsorAin Shams University
About this trial
To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD)
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS < -18% with minimum age of 6 years old.
Disqualifiers
Any patient who refuses to sign an informed consent.
Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.
Reduced ejection fraction below 50%.
Trial design
Design model
Single group
Treatments tested in this trial
Captopril Tablets
DrugPatients will be given captopril to see effect on global longitudinal strain
Treatment groups
20 Participants
are divided into 1 treatment groupGroup A: Duchenne patients subjected to captoprilOther 1 intervention
Trial outcomes
Primary outcomes
1
The impaired global longitudinal strain will change in echo in the number of participants with duchenne myodystrophy
Impaired Global longitudinal strain will be changed in echo after 6 months of treatment with Captopril in patients with duchenne myodystrophy
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov